Accrued Liabilities & Other
Neurocrine Biosciences Accrued Liabilities & Other increased by 14.4% to $120.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $110.00M to $120.00M. Over 3 years (FY 2022 to FY 2025), Accrued Liabilities & Other shows an upward trend with a 15.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
A significant increase may indicate rising operational costs or deferred payments, while a decrease suggests improved cash management or settlement of obligations.
Detailed definition
This represents short-term obligations for expenses incurred but not yet invoiced or paid, alongside miscellaneous curre...
Peer comparison
Standard working capital line item found in almost all corporate balance sheets.
accrued_liabilities_and_other_currentHistorical Data
| Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $67.30M | $93.80M | $133.30M | $87.30M | $107.20M | $95.70M | $109.90M | $110.00M | $104.60M | $119.90M | $104.90M | $120.00M |
| QoQ Change | — | +39.4% | +42.1% | -34.5% | +22.8% | -10.7% | +14.8% | +0.1% | -4.9% | +14.6% | -12.5% | +14.4% |
| YoY Change | — | — | +98.1% | — | — | +2.0% | -17.6% | +26.0% | -2.4% | +25.3% | -4.5% | +9.1% |
Accrued Liabilities & Other at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's accrued liabilities & other?
- Neurocrine Biosciences (NBIX) reported accrued liabilities & other of $120.00M in Q1 2026.
- How has Neurocrine Biosciences's accrued liabilities & other changed year-over-year?
- Neurocrine Biosciences's accrued liabilities & other increased by 9.1% year-over-year, from $110.00M to $120.00M.
- What is the long-term trend for Neurocrine Biosciences's accrued liabilities & other?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's accrued liabilities & other has grown at a 15.9% compound annual growth rate (CAGR), from $67.30M to $104.90M.
- What does accrued liabilities & other mean?
- Short-term debts for expenses the company has incurred but hasn't paid yet.